2.72
-0.01(-0.37%)
Currency In USD
| Previous Close | 2.73 |
| Open | 2.75 |
| Day High | 2.78 |
| Day Low | 2.63 |
| 52-Week High | 5.92 |
| 52-Week Low | 0.52 |
| Volume | 974,970 |
| Average Volume | 1.31M |
| Market Cap | 179.86M |
| PE | -2.34 |
| EPS | -1.16 |
| Moving Average 50 Days | 3.54 |
| Moving Average 200 Days | 3.55 |
| Change | -0.01 |
If you invested $1000 in Neuronetics, Inc. (STIM) since IPO date, it would be worth $97.91 as of October 02, 2025 at a share price of $2.72. Whereas If you bought $1000 worth of Neuronetics, Inc. (STIM) shares 5 years ago, it would be worth $517.11 as of October 02, 2025 at a share price of $2.72.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)
GlobeNewswire Inc.
Sep 17, 2025 12:32 PM GMT
Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation (TMS) servicesMALVERN, Pa., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, develop
Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire Inc.
Aug 04, 2025 8:30 PM GMT
MALVERN, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherev
NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents
GlobeNewswire Inc.
Jul 30, 2025 12:32 PM GMT
Real-world data showing NeuroStar is effective in adolescents and young adults with depression from the world’s largest TMS outcomes datasetMALVERN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology compa